tiprankstipranks
Trending News
More News >

Shandong Xinhua Pharmaceutical Secures Drug Registration for Ivabradine Hydrochloride Tablets

Story Highlights
Shandong Xinhua Pharmaceutical Secures Drug Registration for Ivabradine Hydrochloride Tablets

Don’t Miss TipRanks’ Half-Year Sale

The latest announcement is out from Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ).

Shandong Xinhua Pharmaceutical Company Limited announced that its wholly-owned subsidiary, Shandong Zibo Xincat Pharmaceutical Company Limited, has received a Drug Registration Certificate for its Ivabradine Hydrochloride Tablets from the National Medical Products Administration. This approval marks a significant milestone for the company, enhancing its product portfolio and potentially strengthening its position in the pharmaceutical industry by expanding its offerings in the prescription drug market.

More about Shandong Xinhua Pharmaceutical Company Limited Class H

Shandong Xinhua Pharmaceutical Company Limited is a pharmaceutical company based in China, focusing on the production and distribution of prescription drugs. The company is involved in the development of various pharmaceutical products, with a market focus on both domestic and international markets.

Average Trading Volume: 4,889,496

Technical Sentiment Signal: Buy

Current Market Cap: HK$9.26B

Learn more about 0719 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1